Program Overview:

This program covered the key clinical trial findings and their implications from ESC 2024. The program is intended for cardiovascular specialists and primary care physicians.

Discussion Topics:

• HELIOS-B - Vutrisiran for transthyretin cardiomyopathy
• RESHAPE-HF2 and MATTERHORN - The role of transcatheter mitral valve repair in patients with heart failure
• OCEANIC-AF - How does the factor XI inhibitor asundexian compare vs. apixaban in AF?
• FINEARTS-HF - What is the role of finerenone in HFpEF?
• STROKESTOP II and GUARD-AF – Population screening for AF
• AZALEA-TIMI 71 - Factor XI inhibition and peri-procedural bleeding

Learning Objectives:

Following participation in this program, participants will be able to:

• Identify the clinical implications of the new data presented at ESC 2024
• Examine where the data presented may impact clinical practice guidelines
• Apply the latest evidence-based strategies in clinical practice

Faculty:

• Milan Gupta, MD, FRCPC, FCCS, CPC(HC)
• Narendra Singh, MD, FRCPC, FCCS, FACC, FAHA

This program is NOT accredited.

Mainpro+ participants may earn certified credits by completing a Linking Learning Exercise.

Specialist participants may claim Section 2 credits (up to 2 credits per hour) following completion of a personal learning project (PLP) under Section 2: Self-Learning Activities within the MAINPORT ePortfolio. 

This program was developed by CCRN and has received unrestricted educational grant funding

Program slides:

A copy of the program slides is available for CCRN members with a resource library subscription. View pricing and download options on the Resources tab.